BeiGene, Ltd. (BGNE): Price and Financial Metrics


BeiGene, Ltd. (BGNE)

Today's Latest Price: $210.61 USD

4.77 (-2.21%)

Updated Aug 14 12:07pm

Add BGNE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BGNE Stock Summary

  • With a market capitalization of $19,509,983,356, BeiGene Ltd has a greater market value than 90.22% of US stocks.
  • With a price/sales ratio of 86.82, BeiGene Ltd has a higher such ratio than 96.8% of stocks in our set.
  • As for revenue growth, note that BGNE's revenue has grown -48.23% over the past 12 months; that beats the revenue growth of merely 3.78% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BeiGene Ltd are SRPT, XLRN, SGEN, BBIO, and FOLD.
  • Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to www.beigene.com.
BGNE Daily Price Range
BGNE 52-Week Price Range

BGNE Stock Price Chart Technical Analysis Charts


BGNE Price/Volume Stats

Current price $210.61 52-week high $256.01
Prev. close $215.38 52-week low $114.41
Day low $210.61 Volume 36,937
Day high $214.32 Avg. volume 302,505
50-day MA $204.05 Dividend yield N/A
200-day MA $174.45 Market Cap 18.82B

BeiGene, Ltd. (BGNE) Company Bio


BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.





BGNE Latest News Stream


Event/Time News Detail
Loading, please wait...

BGNE Latest Social Stream


Loading social stream, please wait...

View Full BGNE Social Stream

Latest BGNE News From Around the Web

Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.

Week In Review: BeiGene Signs $540 Million Deal For China Rights To 3 HBV Candidates

Deals and Financing Beijing's BeiGene (NSDQ: [[BGNE]]; HK: 06160) in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus ((HBV)) from Assembly Biosciences (NSDQ: [[ASMB]]) in a $540 million agreement. All three molecules have started US clinical trials. BeiGene, which will make a $40 million upfront payment, is...

ChinaBio Today on Seeking Alpha | July 26, 2020

13Ds Filings

Activist reports to the SEC from July 16 through July 22, 2020, including positions in Anterix, Inventiva, BeiGene, and two other companies

Yahoo | July 24, 2020

The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer ...

Benzinga | July 22, 2020

The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) AstraZeneca plc (NYSE: AZN ) ( announced positive Phase 1/2 readout for the coronavirus vaccine it is co-developing with the Oxford University) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) (reacted to positive late-s...

Benzinga Feeds | July 21, 2020

BeiGene in-licenses Assembly Bio HBV candidates in China

BeiGene (BGNE) inks an agreement with Assembly Biosciences (ASMB) securing exclusive development and commercialization rights in Greater China (Mainland, Macau, Taiwan, Hong Kong) for ABI-H0731, ABI-H2158 and ABI-H3733, three clinical-stage core inhibitor candidates for the treatment of hepatitis B virus ((HBV)) infection.Under the terms of the deal, BGNE will pay...

Seeking Alpha | July 20, 2020

Read More 'BGNE' Stories Here

BGNE Price Returns

1-mo -11.99%
3-mo 26.68%
6-mo 23.10%
1-year 49.17%
3-year 201.00%
5-year N/A
YTD 27.06%
2019 18.18%
2018 43.53%
2017 221.87%
2016 N/A
2015 N/A

Continue Researching BGNE

Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:

BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.908 seconds.